Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891174562> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2891174562 abstract "e14555 Background: Anti-PD1 have produced significant antitumor activity in multiply malignancies, however, resistance to anti-PD1 is becoming increasingly apparent in recent years. Low-dose decitabine, a classical DNA hypomethylating agent, was shown to boost effector T cell function and trigger a T cell-mediated response. This phase I study was designed to assess the safety, immunological effects and antitumor activity of this novel combination in patients with advancedanduntreated lymphomas and solid tumors. Methods: Patients were treated with decitabine (10mg/d on day 1-5) and anti-PD1 (2-3mg/kg, day 8) per 3 weeks. Modified salvage regimens (lymphoma: COP; solid tumors: platinum-based chemotherapy) were allowed to be intermittently inserted for patients with aggressive progression. Treatment continued unless disease progression or severe toxicity. Safety was assessed by CTCAEv4.0, and response by standard international criteria. The phenotype and activity of T cells were periodically measured in peripheral blood by flow cytometry. Results: Todate, 11 patients with heavily treated history and refractory bulky lesions have been enrolled, including 8 with lymphomas (7 NHL, 1 HL resistant to anti-PD1) and 3 with metastatic solid tumors (2 gastric cancers, 1 esophageal cancer) failure to anti-PD1. 5 patients (45%) experienced Grade ≥ 3 toxicities, with 1 taken off due to toxicity, and 1 died of asystole during the term of severe cytokine release syndrome (CRS). The common events of leukocytopenia and CRS were prominent features of anti-PD1 plus decitabine. 9 patients were evaluable for response, 1 HL obtained complete response, 3 NHL and 3 solid tumors achieved partial response, and 2 NHL had stable disease with nearly 20% shrinkage. The frequency of interferon-γ-producing CD8+ T cells in the total CD3+ population was largely increased after anti-PD1 plus decitabine infusion. Conclusions: Decitabine augmented the pro-inflammatory effects of anti-PD1 characterized by systemic inflammation response, and further improved antitumor activity of anti-PD1. Clinical trial information: NCT02961101. Clinical trial information: NCT02961101." @default.
- W2891174562 created "2018-09-27" @default.
- W2891174562 creator A5014070201 @default.
- W2891174562 creator A5017155997 @default.
- W2891174562 creator A5023363049 @default.
- W2891174562 creator A5039909130 @default.
- W2891174562 creator A5045832304 @default.
- W2891174562 creator A5067287490 @default.
- W2891174562 creator A5079316771 @default.
- W2891174562 creator A5081946580 @default.
- W2891174562 creator A5084740517 @default.
- W2891174562 creator A5090356486 @default.
- W2891174562 date "2017-05-20" @default.
- W2891174562 modified "2023-09-28" @default.
- W2891174562 title "Phase I study of anti-PD1 in combination with low-dose decitabine in patients with advanced and untreated malignancies." @default.
- W2891174562 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e14555" @default.
- W2891174562 hasPublicationYear "2017" @default.
- W2891174562 type Work @default.
- W2891174562 sameAs 2891174562 @default.
- W2891174562 citedByCount "2" @default.
- W2891174562 countsByYear W28911745622020 @default.
- W2891174562 countsByYear W28911745622022 @default.
- W2891174562 crossrefType "journal-article" @default.
- W2891174562 hasAuthorship W2891174562A5014070201 @default.
- W2891174562 hasAuthorship W2891174562A5017155997 @default.
- W2891174562 hasAuthorship W2891174562A5023363049 @default.
- W2891174562 hasAuthorship W2891174562A5039909130 @default.
- W2891174562 hasAuthorship W2891174562A5045832304 @default.
- W2891174562 hasAuthorship W2891174562A5067287490 @default.
- W2891174562 hasAuthorship W2891174562A5079316771 @default.
- W2891174562 hasAuthorship W2891174562A5081946580 @default.
- W2891174562 hasAuthorship W2891174562A5084740517 @default.
- W2891174562 hasAuthorship W2891174562A5090356486 @default.
- W2891174562 hasConcept C104317684 @default.
- W2891174562 hasConcept C121608353 @default.
- W2891174562 hasConcept C126322002 @default.
- W2891174562 hasConcept C143998085 @default.
- W2891174562 hasConcept C150194340 @default.
- W2891174562 hasConcept C185592680 @default.
- W2891174562 hasConcept C190727270 @default.
- W2891174562 hasConcept C2777334693 @default.
- W2891174562 hasConcept C2780235182 @default.
- W2891174562 hasConcept C55493867 @default.
- W2891174562 hasConcept C71924100 @default.
- W2891174562 hasConcept C98274493 @default.
- W2891174562 hasConceptScore W2891174562C104317684 @default.
- W2891174562 hasConceptScore W2891174562C121608353 @default.
- W2891174562 hasConceptScore W2891174562C126322002 @default.
- W2891174562 hasConceptScore W2891174562C143998085 @default.
- W2891174562 hasConceptScore W2891174562C150194340 @default.
- W2891174562 hasConceptScore W2891174562C185592680 @default.
- W2891174562 hasConceptScore W2891174562C190727270 @default.
- W2891174562 hasConceptScore W2891174562C2777334693 @default.
- W2891174562 hasConceptScore W2891174562C2780235182 @default.
- W2891174562 hasConceptScore W2891174562C55493867 @default.
- W2891174562 hasConceptScore W2891174562C71924100 @default.
- W2891174562 hasConceptScore W2891174562C98274493 @default.
- W2891174562 hasLocation W28911745621 @default.
- W2891174562 hasOpenAccess W2891174562 @default.
- W2891174562 hasPrimaryLocation W28911745621 @default.
- W2891174562 hasRelatedWork W1603418727 @default.
- W2891174562 hasRelatedWork W1971580118 @default.
- W2891174562 hasRelatedWork W2014409655 @default.
- W2891174562 hasRelatedWork W2017891878 @default.
- W2891174562 hasRelatedWork W2033022308 @default.
- W2891174562 hasRelatedWork W2041789504 @default.
- W2891174562 hasRelatedWork W2148680303 @default.
- W2891174562 hasRelatedWork W2247707042 @default.
- W2891174562 hasRelatedWork W2404658926 @default.
- W2891174562 hasRelatedWork W2409337404 @default.
- W2891174562 hasRelatedWork W2560308210 @default.
- W2891174562 hasRelatedWork W2740815887 @default.
- W2891174562 hasRelatedWork W2800488493 @default.
- W2891174562 hasRelatedWork W2897368980 @default.
- W2891174562 hasRelatedWork W3011659068 @default.
- W2891174562 hasRelatedWork W3092069161 @default.
- W2891174562 hasRelatedWork W3120079658 @default.
- W2891174562 hasRelatedWork W3160364975 @default.
- W2891174562 hasRelatedWork W3187991411 @default.
- W2891174562 hasRelatedWork W2754946310 @default.
- W2891174562 isParatext "false" @default.
- W2891174562 isRetracted "false" @default.
- W2891174562 magId "2891174562" @default.
- W2891174562 workType "article" @default.